Clinical Trial

Treatment of Prostate Cancer

Study Description

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Rucaparib

Rucaparib will be administered daily.

Drug - Abiraterone acetate or Enzalutamide or Docetaxel

Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.

Additional Information

Official Study Title

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Clinical Trial ID

NCT02975934

ParticipAid ID

RdG2Lb